- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 40FR12B Initial registration of securities (Canada)
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- 99.13 Exhibit 99.13
- 99.14 Exhibit 99.14
- 99.15 Exhibit 99.15
- 99.16 Exhibit 99.16
- 99.17 Exhibit 99.17
- 99.18 Exhibit 99.18
- 99.19 Exhibit 99.19
- 99.20 Exhibit 99.20
- 99.21 Exhibit 99.21
- 99.22 Exhibit 99.22
- 99.23 Exhibit 99.23
- 99.24 Exhibit 99.24
- 99.25 Exhibit 99.25
- 99.26 Exhibit 99.26
- 99.27 Exhibit 99.27
- 99.28 Exhibit 99.28
- 99.29 Exhibit 99.29
- 99.30 Exhibit 99.30
- 99.31 Exhibit 99.31
- 99.32 Exhibit 99.32
- 99.33 Exhibit 99.33
- 99.34 Exhibit 99.34
- 99.35 Exhibit 99.35
- 99.36 Exhibit 99.36
- 99.37 Exhibit 99.37
- 99.38 Exhibit 99.38
- 99.39 Exhibit 99.39
- 99.40 Exhibit 99.40
- 99.41 Exhibit 99.41
- 99.42 Exhibit 99.42
- 99.43 Exhibit 99.43
- 99.44 Exhibit 99.44
- 99.45 Exhibit 99.45
- 99.46 Exhibit 99.46
- 99.47 Exhibit 99.47
- 99.48 Exhibit 99.48
- 99.49 Exhibit 99.49
- 99.50 Exhibit 99.50
- 99.51 Exhibit 99.51
- 99.52 Exhibit 99.52
- 99.53 Exhibit 99.53
- 99.54 Exhibit 99.54
- 99.55 Exhibit 99.55
- 99.56 Exhibit 99.56
- 99.57 Exhibit 99.57
- 99.58 Exhibit 99.58
- 99.59 Exhibit 99.59
- 99.60 Exhibit 99.60
- 99.61 Exhibit 99.61
- 99.62 Exhibit 99.62
- 99.63 Exhibit 99.63
- 99.64 Exhibit 99.64
- 99.65 Exhibit 99.65
- 99.66 Exhibit 99.66
- 99.67 Exhibit 99.67
- 99.68 Exhibit 99.68
- 99.69 Exhibit 99.69
- 99.70 Exhibit 99.70
- 99.71 Exhibit 99.71
- 99.72 Exhibit 99.72
- 99.73 Exhibit 99.73
- 99.74 Exhibit 99.74
- 99.75 Exhibit 99.75
- 99.76 Exhibit 99.76
- 99.77 Exhibit 99.77
- 99.78 Exhibit 99.78
- 99.79 Exhibit 99.79
- 99.80 Exhibit 99.80
- 99.81 Exhibit 99.81
- 99.82 Exhibit 99.82
- 99.83 Exhibit 99.83
- 99.84 Exhibit 99.84
- 99.85 Exhibit 99.85
- 99.86 Exhibit 99.86
- 99.87 Exhibit 99.87
- 99.88 Exhibit 99.88
- 99.89 Exhibit 99.89
- 99.90 Exhibit 99.90
- 99.91 Exhibit 99.91
- 99.92 Exhibit 99.92
- 99.93 Exhibit 99.93
- 99.94 Exhibit 99.94
- 99.95 Exhibit 99.95
- 99.96 Exhibit 99.96
- 99.97 Exhibit 99.97
- 99.98 Exhibit 99.98
- 99.99 Exhibit 99.99
- 99.100 Exhibit 99.100
- 99.101 Exhibit 99.101
- 99.102 Exhibit 99.102
- 99.103 Exhibit 99.103
- 99.104 Exhibit 99.104
- 99.105 Exhibit 99.105
- 99.106 Exhibit 99.106
- 99.107 Exhibit 99.107
- 99.108 Exhibit 99.108
- 99.109 Exhibit 99.109
- 99.110 Exhibit 99.110
- 99.111 Exhibit 99.111
- 99.112 Exhibit 99.112
- 99.113 Exhibit 99.113
- 99.114 Exhibit 99.114
- 99.115 Exhibit 99.115
- 99.116 Exhibit 99.116
- 99.117 Exhibit 99.117
- 99.118 Exhibit 99.118
- 99.119 Exhibit 99.119
- 99.120 Exhibit 99.120
- 99.121 Exhibit 99.121
- 99.122 Exhibit 99.122
- 99.123 Exhibit 99.123
- 99.124 Exhibit 99.124
- 99.125 Exhibit 99.125
- 99.126 Exhibit 99.126
- 99.127 Exhibit 99.127
- 99.128 Exhibit 99.128
- 99.129 Exhibit 99.129
- 99.130 Exhibit 99.130
- 99.131 Exhibit 99.131
- 99.132 Exhibit 99.132
- 99.133 Exhibit 99.133
- 99.134 Exhibit 99.134
- 99.135 Exhibit 99.135
- 99.136 Exhibit 99.136
- 99.137 Exhibit 99.137
- 99.138 Exhibit 99.138
- 99.139 Exhibit 99.139
- 99.140 Exhibit 99.140
- 99.141 Exhibit 99.141
- 99.142 Exhibit 99.142
- 99.143 Exhibit 99.143
- 99.144 Exhibit 99.144
- 99.145 Exhibit 99.145
- 99.146 Exhibit 99.146
- 99.147 Exhibit 99.147
- 99.148 Exhibit 99.148
- 99.149 Exhibit 99.149
- 99.150 Exhibit 99.150
- 99.151 Exhibit 99.151
- 99.152 Exhibit 99.152
- 99.153 Exhibit 99.153
- 99.154 Exhibit 99.154
- 99.155 Exhibit 99.155
- 99.156 Exhibit 99.156
- 99.157 Exhibit 99.157
- 99.158 Exhibit 99.158
- 99.159 Exhibit 99.159
- 99.160 Exhibit 99.160
- 99.161 Exhibit 99.161
- 99.162 Exhibit 99.162
- 99.163 Exhibit 99.163
- 99.164 Exhibit 99.164
- 99.165 Exhibit 99.165
- 99.166 Exhibit 99.166
- 99.167 Exhibit 99.167
- 99.168 Exhibit 99.168
- 99.169 Exhibit 99.169
- 99.170 Exhibit 99.170
- 99.171 Exhibit 99.171
- 99.172 Exhibit 99.172
- 99.173 Exhibit 99.173
- 99.174 Exhibit 99.174
Zentek Wins ISC Challenge to Develop
a Portable Detection Device for SARS-CoV-2
in Wastewater
Guelph, ON - November 4, 2021, Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN) and OTC:PINK:ZENYF), a Canadian, IP development and commercialization company focused on next-gen healthcare solutions, announces it has been selected as one of three technologies for phase 1 of the Innovation Solutions Canada (ISC) challenge to develop a portable detection device for SARS-CoV-2 in wastewater. ZEN has received a $148,000 award from ISC to develop its first prototype.
"Our success in this ISC challenge is an important extension of Zentek's rapid detection platform based on the patent-pending DNA aptamer technology licensed from McMaster University. Although initial applications have been focused on rapid detection of SARS-CoV-2 in saliva, we believe that in working with our collaborators, we can expand the application to track the prevalence and potential spread of pathogens through detection in wastewater as well. This is further validation of our technology as a platform not only for the development of new aptamers to detect different pathogens, but also detecting pathogens in different ways. This award and challenge confirm the emphasis that the Government of Canada is placing on pathogen detection systems. We anticipate similar interest from other end users who are interested in early detection of pathogen outbreaks like cruise ships and among vulnerable or isolated populations," commented Greg Fenton, Zentek CEO.
ISC Challenge Overview
Zentek, in partnership with Dr. Yingfu Li, Dr. John Brennan, and Dr. Leyla Soleymani at McMaster University and Forsee Instruments Ltd., have been chosen to develop a prototype based on the Company's patent-pending aptamer-based saliva sensor to detect SARS-CoV-2 in wastewater samples within the next 4 months. The goal of the ISC challenge, sponsored by the Public Health Agency of Canada and the National Research Council of Canada, is to produce a portable end-to-end SARS-CoV-2 wastewater detection device used for wastewater monitoring and designed to remove delays in the test-to-result pipeline. An additional goal is to provide important outbreak surveillance data to public health units. The challenge is a competitive process whereby one solution that reaches the objectives of the program will receive $350,000 to further develop the prototype into a final, commercial-ready solution.
About Zentek Ltd.
Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuardTM, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at www.ZENGraphene.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.ca.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.